Answers are grounded in this paper and cite their sources.
The Fat Mass and Obesity-Associated ( FTO ) gene has been implicated in susceptibility to type 2 diabetes mellitus (T2DM), though findings across populations remain inconsistent. This meta-analysis evaluated the association between two FTO polymorphisms, rs9939609 and rs8050136, and T2DM risk, alongside associated metabolic outcomes, in Indian and global cohorts. A systematic search identified case-control studies reporting genotype distributions of FTO rs9939609 and rs8050136 among T2DM and normal glucose tolerance (NGT) subjects. Following peer review, the search strategy was broadened and six additional Indian studies suggested by the reviewers were assessed against the eligibility criteria. Study quality was assessed using the Newcastle-Ottawa Scale (NOS). Pooled odds ratios (OR) were calculated under dominant, recessive, and allele genetic models using RevMan 5.4 (random-effects where I² > 50%). Clinical outcomes (BMI, waist circumference, total cholesterol, triglycerides, LDL, and HDL) were pooled as mean differences (MD). Heterogeneity was assessed using the I² statistic, with leave-one-out and subgroup sensitivity analyses and, for the clinical outcomes, a sensitivity analysis retaining a single representative report from the overlapping CURES cohort. PRISMA guidelines were followed throughout the systematic review and meta analysis. Fifteen studies met inclusion criteria (thirteen contributing genetic association data and two contributing clinical outcome data only). Both FTO variants showed significant positive associations with T2DM under the dominant and allele models, and rs9939609 also under the recessive model (OR range 1.14–1.31), whereas the rs8050136 recessive model was not significant (OR 1.07, 95% CI 0.93–1.21, p = 0.34). Between-study heterogeneity was low to moderate (I² 9%–60%) and the findings were robust to leave-one-out analyses. For rs8050136, the pooled estimate was smaller and less precise in Indian studies (allele model OR 1.13, 95% CI 0.96–1.32) than in non-Indian studies (OR 1.19, 95% CI 1.10–1.28). T2DM subjects had higher BMI, total cholesterol, triglycerides, and LDL, and lower HDL, than NGT controls; however, heterogeneity was very high for the lipid outcomes, and when only one representative report from the overlapping CURES cohort was retained, the direction of every difference was preserved but only BMI remained statistically significant. FTO rs9939609 and rs8050136 are associated with modestly increased T2DM susceptibility (pooled OR 1.14–1.31), with a consistent direction of effect across most genetic models, although the evidence for rs8050136 in Indian populations is weaker and more heterogeneous. T2DM patients had higher BMI and a less favourable lipid profile than NGT controls, but these comparisons were not stratified by genotype, rest on a small number of partly overlapping studies and show very high heterogeneity; they therefore do not show that the metabolic differences are attributable to the risk genotype. These findings support FTO as a genetic risk marker for T2DM in the populations studied.
No takes yet. Share an insight, caveat, or question.
R et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: